title: Response to single-agent thalidomide and eligibility to undergo autotransplant for patients with multiple myeloma refractory to VAD.
authors.forename: J H
authors.initials: JH
authors.lastname: Milone
authors.forename: V
authors.initials: V
authors.lastname: Prates
authors.forename: J
authors.initials: J
authors.lastname: Bordone
authors.forename: J
authors.initials: J
authors.lastname: Napal
authors.forename: C
authors.initials: C
authors.lastname: Garcia
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D003561:Cytarabine; D003907:Dexamethasone; D019008:Drug Resistance, Neoplasm; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy*; D018579:Patient Selection; D016879:Salvage Therapy / Q000379:methods; D013792:Thalidomide / Q000008:administration & dosage*; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014750:Vincristine
chemical_list: D003561:Cytarabine; D013792:Thalidomide; D014750:Vincristine; D003907:Dexamethasone